These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

86 related articles for article (PubMed ID: 8693958)

  • 21. Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics.
    Ellis MJ; Tao Y; Luo J; A'Hern R; Evans DB; Bhatnagar AS; Chaudri Ross HA; von Kameke A; Miller WR; Smith I; Eiermann W; Dowsett M
    J Natl Cancer Inst; 2008 Oct; 100(19):1380-8. PubMed ID: 18812550
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Clinical studies on endocrine therapy of prostatic carcinoma (1): Multivariate analyses of prognostic factors in patients with prostatic carcinoma given endocrine therapy].
    Kumamoto Y; Tsukamoto T; Umehara T; Shimazaki J; Fuse H; Ohshima H; Takeuchi H; Yoshida O; Okada K; Saito Y
    Hinyokika Kiyo; 1990 Mar; 36(3):275-84. PubMed ID: 2191569
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma.
    Motzer RJ; Bacik J; Schwartz LH; Reuter V; Russo P; Marion S; Mazumdar M
    J Clin Oncol; 2004 Feb; 22(3):454-63. PubMed ID: 14752067
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prognostic significance of prostate-specific antigen levels two months after hormonal manipulation of metastatic prostate cancer.
    Kawakami S; Takagi K; Yonese J; Ueda T; Fukui I; Kawai T
    Eur Urol; 1997; 32(1):58-63. PubMed ID: 9266233
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors.
    Brown JE; Cook RJ; Major P; Lipton A; Saad F; Smith M; Lee KA; Zheng M; Hei YJ; Coleman RE
    J Natl Cancer Inst; 2005 Jan; 97(1):59-69. PubMed ID: 15632381
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Association of body mass index with response and survival in men with metastatic prostate cancer: Southwest Oncology Group trials 8894 and 9916.
    Montgomery RB; Goldman B; Tangen CM; Hussain M; Petrylak DP; Page S; Klein EA; Crawford ED;
    J Urol; 2007 Nov; 178(5):1946-51; discussion 1951. PubMed ID: 17868721
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Evolution and prognostic factors of adenocarcinomas of the prostate metastasizing at diagnosis].
    Arrizabalaga Moreno M; García González JI; Mora Durvan M; Díez Rodríguez JM; Esteban Artiaga R; Navarro Sebastián J; Castro Pita M; Paniagua Andrés P
    Actas Urol Esp; 1997 Sep; 21(8):724-36. PubMed ID: 9412221
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Dynamics of prostate-specific antigen as prognostic factors in endocrine treatment for prostate cancer].
    Horiguchi A; Hatakeyama N; Ikeuchi K
    Hinyokika Kiyo; 1999 Jan; 45(1):31-5. PubMed ID: 10086263
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Multivariate analysis of prognostic factors in patients with prostatic cancer].
    Miyamoto T; Yuasa M; Furukawa A; Tamura M; Kawanishi Y; Numata A; Imagawa A; Kagawa S
    Hinyokika Kiyo; 1991 Dec; 37(12):1663-8. PubMed ID: 1785390
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prognostic factors in prostate cancer.
    Stattin P
    Scand J Urol Nephrol Suppl; 1997; 185():1-46. PubMed ID: 9249905
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Risk factors for progression in patients with prostate cancer treated with radical prostatectomy.
    Lerner SE; Blute ML; Zincke H
    Semin Urol Oncol; 1996 May; 14(2 Suppl 2):12-20; discussion 21. PubMed ID: 8725887
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prognostic factors in patients with advanced stage prostate cancer.
    Emrich LJ; Priore RL; Murphy GP; Brady MF
    Cancer Res; 1985 Oct; 45(10):5173-9. PubMed ID: 4027993
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Finnish multicenter study comparing intermittent to continuous androgen deprivation for advanced prostate cancer: interim analysis of prognostic markers affecting initial response to androgen deprivation.
    Salonen AJ; Viitanen J; Lundstedt S; Ala-Opas M; Taari K; Tammela TL;
    J Urol; 2008 Sep; 180(3):915-9; discussion 919-20. PubMed ID: 18635219
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prognostic factors in metastatic melanoma patients treated with biochemotherapy and maintenance immunotherapy.
    Minor DR; Moore D; Kim C; Kashani-Sabet M; Venna SS; Wang W; Boasberg P; O'Day S
    Oncologist; 2009 Oct; 14(10):995-1002. PubMed ID: 19776094
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Changes in chromogranin a serum levels during endocrine therapy in metastatic prostate cancer patients.
    Sasaki T; Komiya A; Suzuki H; Shimbo M; Ueda T; Akakura K; Ichikawa T
    Eur Urol; 2005 Aug; 48(2):224-9; discussion 229-30. PubMed ID: 16005374
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Prognostic factors in low-grade lymphoma].
    Gandarillas MA; Conde E; Mazorra F; Cuadrado MA; Baro J; Garijo J; Recio M; Richard C; Iriondo A; Zubizarreta A
    Sangre (Barc); 1998 Jun; 43(3):185-90. PubMed ID: 9741223
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Staging for prostate cancer: time to incorporate pretreatment prostate-specific antigen and Gleason score?
    Roach M; Weinberg V; Sandler H; Thompson I
    Cancer; 2007 Jan; 109(2):213-20. PubMed ID: 17167758
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Adjuvant treatment after radical prostatectomy in prostatic carcinoma (pT3 or pTxN+): prognostic factors and results].
    Zincke H
    Praxis (Bern 1994); 1997 Nov; 86(46):1825-32. PubMed ID: 9454284
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prognostic value of serum markers for prostate cancer.
    Stenman UH; Abrahamsson PA; Aus G; Lilja H; Bangma C; Hamdy FC; Boccon-Gibod L; Ekman P
    Scand J Urol Nephrol Suppl; 2005 May; (216):64-81. PubMed ID: 16019759
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Evaluation of selected clinical prognostic factors in patients with non-granulomatous lymphomas].
    Rolski J
    Pol Merkur Lekarski; 1997 May; 2(11):324-6. PubMed ID: 9377682
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.